Ikarian Capital’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Ikarian Capital’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-400,000	Closed	-$2.4M	–	119
2022 Q3	$2.4M	Buy	+400,000	New	+$2.27M	0.48%	55

Ikarian Capital's STSA Position: Q2 2023 in Review

Ikarian Capital sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 136,059 shares — an estimated $95K sold.

Ikarian Capital first reported a position in STSA in Q2 2020 and held it in 10 quarters. The position peaked at $9.46M in Q2 2020. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.

Ikarian Capital reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Ikarian Capital sold 136,059 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $95K.
Ikarian Capital first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
Ikarian Capital's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $9.46M in Q2 2020.
0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.